Home / Central Data Catalog / FRESH-PEF2831-EN
central

Effectiveness and Use of Levetiracetam of pediatrics in real life

France, 2007 - 2008
Reference ID
FRESH-PEF2831-en
Producer(s)
Annie;FOURRIER-REGLAT, Nicholas;MOORE
Metadata
DDI/XML JSON
Study website Interactive tools
Created on
Feb 18, 2026
Last modified
Feb 18, 2026
Page views
39
  • Identification
  • Scope
  • Coverage
  • Producers and sponsors
  • Study authorization
  • Sampling
  • Survey instrument
  • Data collection
  • Study activities
  • Access policy
  • Data Access
  • Contacts

    • Identification

    Survey ID number

    FRESH-PEF2831-en
    Title

    Effectiveness and Use of Levetiracetam of pediatrics in real life
    Abbreviation or Acronym

    EULEVp
    Country
    Name Country code
    France fr
    Kind of Data

    ['Clinical data']
    Unit of Analysis

    Individuals

    Scope

    Topics
    Topic Vocabulary
    Neurology health theme
    Healthcare system determinants: Use of care health determinant
    Healthcare system determinants health determinant
    Keywords
    Levetiracetam child effectiveness prescribing patterns pharmaco-epidemiology cohort Department of Pharmacology Bordeaux

    Coverage

    Universe

    {"level_sex_clusion_I":[{"value":"Male","concept":{"vocab":"MeSH","vocabURI":"D008297"}},{"value":"Female","concept":{"vocab":"MeSH","vocabURI":"D005260"}}],"level_age_clusion_I":[{"value":"Infant, Newborn (birth to 28 days)","concept":{"vocab":"MeSH","vocabURI":"D007231"}},{"value":"Infant (28 days to 2 years)","concept":{"vocab":"MeSH","vocabURI":"D007223"}},{"value":"Child, Preschool (2 to 5 years)","concept":{"vocab":"MeSH","vocabURI":"D002675"}},{"value":"Child (6 to 12 years)","concept":{"vocab":"MeSH","vocabURI":"D002648"}},{"value":"Adolescent (13 to 18 years)","concept":{"vocab":"MeSH","vocabURI":"D000293"}}],"level_type_clusion_I":"Patients population","level_type_clusion_other":"","clusion_I":"Patient aged under 16 years; Obtainment of consent from the guardian of the child; patient having initiated treatment with levetiracetam between 01/10/2006 and 31/03/2007 (whether or not the treatment was continued), and having never been previously treated with levetiracetam; patient who may be followed over the following 12 months; Patient not participating in a clinical trial (Huriet-Sérusclat).","clusion_E":""}

    Producers and sponsors

    Primary investigators
    Name
    Annie;FOURRIER-REGLAT
    Nicholas;MOORE
    Producers
    Name Role
    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) sponsor
    Funding Agency/Sponsor
    Name
    UCB PHARMA (FRANCE)

    Study authorization

    Agency
    Agency name
    CNIL
    CESREES

    Sampling

    Sample frame

    Unit Type

    ['Through organizations (health services or institutions, schools, businesses, etc.)']
    Sampling Procedure

    ['{"concept":{"vocabURI":"Other","vocab":"CESSDA"},"value":"Other"}']

    Survey instrument

    Questionnaires

    Access on specific project only
    Methodology notes

    Observational Study

    Data collection

    Dates of Data Collection
    Start End
    2007-01-01 2008-01-01
    Mode of data collection
    • {"concept":{"vocabURI":"Interview","vocab":"CESSDA"},"value":"Interview with the participant (including clinical)"}

    Study activities

    Study activities
    Type
    primary evaluation
    Description
    Health event/morbidity Health event/mortality Health care consumption and services

    Access policy

    Notes

    Ownership of study data is the subject of an agreement between the University of Bordeaux Segalen and the funder.

    Data Access

    Availability Status

    {"value":"To be defined","extLink":[]}

    Contacts

    Contacts
    Name Email
    Annie;FOURRIER-REGLAT annie.fourrier-reglat@u-bordeaux.fr
    Nicholas;MOORE nicholas.moore@u-bordeaux.fr
    Back to Catalog